<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333462</url>
  </required_header>
  <id_info>
    <org_study_id>NB-1008-001</org_study_id>
    <nct_id>NCT01333462</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008</brief_title>
  <official_title>A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (FluzoneÂ® + 60%W805EC) in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoBio Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoBio Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and immune response of a new intranasal&#xD;
      vaccine against influenza, called NB-1008. The vaccine is composed of a licensed vaccine that&#xD;
      is normally given as an injection, called Fluzone, and an adjuvant (additive that helps a&#xD;
      vaccine work better), called W805EC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>365 Days</time_frame>
    <description>Adverse events (AE) collected through Day 28 and Serious Adverse Events (SAE) collected through Day 365.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum hemagglutination-inhibition (HAI) Geometric Mean Titer (GMT) and proportion of Volunteers with &gt;=4 fold increase in titer as well as proportion of volunteers with titer &gt;= protective level of 40</measure>
    <time_frame>Day 28 and Day 60</time_frame>
    <description>HAI antibody titers to H1N1, H3N2, and B influenza strains contained in the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal wash anti-Fluzone IgA Geometric Mean Titer (GMT) and proportion of volunteers with &gt;=4 fold increase in GMT anti-Fluuzone IgA titer</measure>
    <time_frame>Day 28 and Day 60</time_frame>
    <description>Nasal Wash IgA to Fluzone.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Phosphate Buffered Saline (PBS) IN</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone 4 mcg HA IN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone 15 mcg HA IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 4 mcg HA 5% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 4 mcg HA 10% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 4 mcg HA 15% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 4 mcg HA 20% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone 10 mcg HA IN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 10 mcg HA 5% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 10 mcg HA 10% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 10 mcg HA 15% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-1008 10 mcg HA 20% W805EC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NB-1008</intervention_name>
    <description>NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.</description>
    <arm_group_label>NB-1008 10 mcg HA 10% W805EC</arm_group_label>
    <arm_group_label>NB-1008 10 mcg HA 15% W805EC</arm_group_label>
    <arm_group_label>NB-1008 10 mcg HA 20% W805EC</arm_group_label>
    <arm_group_label>NB-1008 10 mcg HA 5% W805EC</arm_group_label>
    <arm_group_label>NB-1008 4 mcg HA 10% W805EC</arm_group_label>
    <arm_group_label>NB-1008 4 mcg HA 15% W805EC</arm_group_label>
    <arm_group_label>NB-1008 4 mcg HA 20% W805EC</arm_group_label>
    <arm_group_label>NB-1008 4 mcg HA 5% W805EC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>The controls include PBS placebo control as well as Fluzone IN and IM active controls.</description>
    <arm_group_label>Fluzone 10 mcg HA IN</arm_group_label>
    <arm_group_label>Fluzone 15 mcg HA IM</arm_group_label>
    <arm_group_label>Fluzone 4 mcg HA IN</arm_group_label>
    <arm_group_label>Phosphate Buffered Saline (PBS) IN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female.&#xD;
&#xD;
          2. Are 18-49 years of age, inclusive.&#xD;
&#xD;
          3. If female, must be non-pregnant as confirmed by a negative serum pregnancy test&#xD;
             conducted at screening and a negative urine pregnancy test conducted at the site&#xD;
             within 24 hours preceding receipt of vaccine.&#xD;
&#xD;
          4. Females who are not surgically sterile or at least one year post-menopausal agree to&#xD;
             use oral, implantable, transdermal or injectable contraceptive or another reliable&#xD;
             form of contraception approved by the Investigator for a minimum of 30 days prior to&#xD;
             vaccination and for 3 months following vaccination.&#xD;
&#xD;
          5. Healthy, as determined by medical history, physical examination, vital signs, and&#xD;
             clinical laboratory examinations.&#xD;
&#xD;
          6. Comprehension of the study requirements, expressed availability for the required study&#xD;
             period, and ability to attend scheduled visits.&#xD;
&#xD;
          7. Has given written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of significant acute or chronic, uncontrolled medical or psychiatric illness&#xD;
             (institution of new medical or surgical treatment, or a significant dose alteration&#xD;
             for uncontrolled symptoms or drug toxicity within 3 months). Subjects with a history&#xD;
             of chronic cough, frequent sinus infections, sinusitis, allergic rhinitis, nasal&#xD;
             polyps or obstruction, including deviated septum significant enough to obstruct the&#xD;
             nasal openings are to be excluded. Subjects with seasonal rhinitis may be included if&#xD;
             their 'season' does not occur within 3 months of the vaccination date and they are not&#xD;
             currently receiving intranasal steroids.&#xD;
&#xD;
          2. Receipt of the 2008-2009 influenza vaccine.&#xD;
&#xD;
          3. Positive serology for HIV-1 or HIV-2, or HCV antibodies.&#xD;
&#xD;
          4. Platelet count &lt;150,000/mm3.&#xD;
&#xD;
          5. Positive urine drug screen.&#xD;
&#xD;
          6. History of aspiration, dysphagia, swallowing disorders, stroke or other neurologic&#xD;
             conditions that may predispose the subject to aspiration of test articles into the&#xD;
             respiratory tract.&#xD;
&#xD;
          7. History of Bell's palsy.&#xD;
&#xD;
          8. Cancer or treatment for cancer, within 3 years. Subjects with a history of cancer who&#xD;
             are disease-free without treatment for 3 years or more are eligible. Basal cell&#xD;
             carcinoma (BCC) or (SCC) are allowed, unless present on or near the nose.&#xD;
&#xD;
          9. Impaired immune responsiveness, regardless of cause, including diabetes mellitus.&#xD;
&#xD;
         10. Presently receiving or history of receiving any medications or treatments that affects&#xD;
             the immune system such as immune globulin, interferon, immunomodulators, cytotoxic&#xD;
             drugs or drugs known to be frequently associated with significant major organ&#xD;
             toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months.&#xD;
&#xD;
         11. Chronic use of inhaled or intranasal sprays including decongestants and&#xD;
             corticosteroids.&#xD;
&#xD;
         12. Presently a smoker or tobacco user or have a history of smoking or tobacco use within&#xD;
             the past year prior to screening.&#xD;
&#xD;
         13. Receipt or planned administration of a nonstudy vaccine within 30 days before the&#xD;
             study, including licensed influenza vaccines and prior to the Day 60 telephone&#xD;
             contact. Immunization on an emergency basis with Tetanus Toxoids Adsorbed for adult&#xD;
             use (Td or Tdap) up to 8 days before or at least 8 days after a dose of study vaccine&#xD;
             will be allowed. Administration of study vaccine can be delayed if a nonstudy vaccine&#xD;
             has been administered and will be given as soon as acceptable, as described above.&#xD;
&#xD;
         14. Known allergy to any vaccine component, including eggs, egg products, or thimerosal.&#xD;
&#xD;
         15. History of allergic and/or anaphylactic type reaction to injected vaccines or to any&#xD;
             of the components of NB-1008 [soybean oil, dehydrated alcohol (anhydrous ethanol),&#xD;
             polysorbate (Tween 80) and cetylpyridinium chloride (CPC)].&#xD;
&#xD;
         16. History of drug or chemical abuse in the year before the study.&#xD;
&#xD;
         17. Receipt of any investigational product or nonregistered drug within the 30 days before&#xD;
             study entry or currently enrolled in any investigational drug study or intends to&#xD;
             enroll in such a study within the ensuing 6 month period.&#xD;
&#xD;
         18. Use of nasally administered prescription or over-the-counter (OTC) medications within&#xD;
             7 days before vaccination&#xD;
&#xD;
         19. Receipt of blood or blood products 8 weeks before study entry or planned&#xD;
             administration prior to the Day 60 telephone contact.&#xD;
&#xD;
         20. Donation of blood or blood products within 8 weeks before study entry or at any time&#xD;
             up to the Day 28 clinic visit.&#xD;
&#xD;
         21. Acute disease within a week prior to vaccination, defined as the presence of a&#xD;
             moderate or severe illness (as determined by the investigator through medical history&#xD;
             and physical examination) with or without fever. For subjects with a minor illness,&#xD;
             such as diarrhea, or mild upper respiratory tract infection with or without low-grade&#xD;
             febrile illness, the subject can be re-screened once they have complexly recovered.&#xD;
&#xD;
         22. Any condition that, in the opinion of the investigator, might interfere with study&#xD;
             objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jakub Simon, MD, MS/ Director, Clinical Vaccine Development</name_title>
    <organization>NanoBio Corporation</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

